1396312-30-3 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
[1,2,4]triazolo[1,5-a]pyridin-7-amine is used as a key component in pharmaceutical research and drug development due to its distinctive structure and properties. Its ability to interact with various biological targets makes it a promising candidate for the creation of novel therapeutic agents.
Used in Chemical Biology and Medicinal Chemistry:
In the field of chemical biology and medicinal chemistry, [1,2,4]triazolo[1,5-a]pyridin-7-amine is utilized as a building block for the synthesis of various bioactive compounds and pharmaceuticals. Its unique structure allows for the development of new molecules with potential therapeutic applications.
Used in Synthesis of Bioactive Compounds:
[1,2,4]triazolo[1,5-a]pyridin-7-amine is also used as a starting material for the synthesis of bioactive compounds. Its presence in the molecular structure can contribute to the overall activity and efficacy of the resulting compounds, making it a valuable asset in the development of new drugs and pharmaceuticals.
Check Digit Verification of cas no
The CAS Registry Mumber 1396312-30-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,9,6,3,1 and 2 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1396312-30:
(9*1)+(8*3)+(7*9)+(6*6)+(5*3)+(4*1)+(3*2)+(2*3)+(1*0)=163
163 % 10 = 3
So 1396312-30-3 is a valid CAS Registry Number.
1396312-30-3Relevant articles and documents
Synthesis and biological evaluation of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives as novel, potent of ALK5 receptor inhibitors
Wang, Hai,Wang, Xiaowei,Wang, Zhenwei,Yu, Zhuangzhuang,Zhang, Yan,Zhao, Liwen
supporting information, (2022/02/16)
The transforming growth factor type β receptor I (TGF-β R1, also known as activin-like kinase 5 or ALK5) plays a significant role in the pathogenesis of multiple diseases such as malignant tumors and tissue fibrosis. Specific inhibition of ALK5 provides a novel method for controlling the development of cancers and fibrotic diseases. Herein, a novel series of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives was synthesized and identified as ALK5 inhibitors. Among them, compound 8h inhibited ALK5 autophosphorylation and NIH3T3 cell activity with IC50 values of 25 nM and 74.6 nM, respectively. Compound 8h also showed favorable pharmacokinetic profile and ameliorated hERG inhibition. More importantly, 30 mg/kg oral administration of 8h could significantly induce tumour growth inhibition in CT26 xenograft model without obvious toxicity.
